NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $23,000 | -32.4% | 1,417 | -3.5% | 0.00% | – |
| Q2 2020 | $34,000 | -39.3% | 1,469 | -44.2% | 0.00% | – |
| Q1 2020 | $56,000 | 0.0% | 2,634 | 0.0% | 0.00% | – |
| Q4 2019 | $56,000 | +19.1% | 2,634 | 0.0% | 0.00% | – |
| Q3 2019 | $47,000 | -49.5% | 2,634 | -0.2% | 0.00% | – |
| Q2 2019 | $93,000 | +5.7% | 2,638 | 0.0% | 0.00% | – |
| Q1 2019 | $88,000 | +2.3% | 2,638 | +0.2% | 0.00% | – |
| Q4 2018 | $86,000 | +258.3% | 2,634 | +430.0% | 0.00% | – |
| Q2 2018 | $24,000 | -7.7% | 497 | +11.4% | 0.00% | – |
| Q1 2018 | $26,000 | 0.0% | 446 | 0.0% | 0.00% | – |
| Q4 2017 | $26,000 | +2500.0% | 446 | +643.3% | 0.00% | – |
| Q3 2016 | $1,000 | -95.7% | 60 | -97.2% | 0.00% | – |
| Q3 2015 | $23,000 | -14.8% | 2,169 | 0.0% | 0.00% | – |
| Q2 2015 | $27,000 | +17.4% | 2,169 | 0.0% | 0.00% | – |
| Q1 2015 | $23,000 | -30.3% | 2,169 | 0.0% | 0.00% | – |
| Q4 2014 | $33,000 | – | 2,169 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |